Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207441 | 0.81 | FAAH (0.52) | ACLYHTR2CHTR2AKCNH2MMP2 | |
| SCHEMBL3201949 | 0.77 | EPHX2 (0.50) | ACLYHTR2CHTR2AKCNH2MMP2 | |
| SCHEMBL3201870 | 0.77 | HTR2C (0.49) | ACLYSCN3AHTR2CHTR2AKCNH2 | |
| SCHEMBL3222016 | 0.77 | HTR2C (0.49) | ACLYSCN3AHTR2CHTR2AKCNH2 | |
| SCHEMBL3221924 | 0.75 | HTR2C (0.42) | ACLYSCN3AHTR2CHTR2AKCNH2 | |
| SCHEMBL3212904 | 0.75 | POLB (0.59) | MAPTLMNASMN1; SMN2 | |
| SCHEMBL3223105 | 0.74 | KMT2A (0.60) | ACLYMMP2MMP13LMNASMN1; SMN2 | |
| SCHEMBL3217954 | 0.74 | MAPT (0.57) | ACLYHTR2CHTR2AKCNH2FPR2 | |
| SCHEMBL11944169 | 0.74 | POLB (0.49) | HTR6HTR2AMAPTLMNATP53 | |
| SCHEMBL3198980 | 0.74 | NPC1 (0.61) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | HTR6 2021/4885ACLY 1968/4885SCN3A 2214/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | HTR6 1213/4885ACLY 2169/4885SCN3A 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.